The Scottish Medicines Consortium has approved osimertinib for adults with unresectable stage III EGFR-mutant NSCLC whose disease has not progressed after platinum-based chemoradiation.

The BRAF-mutated NSCLC market is poised for growth due to an increasing incidence rate across 7MM. Currently, only one approved therapy, the Tafinlar and Mekinist combo, targets this mutation.

A national cohort study compares the safety and efficacy of weight-based and fixed-dose pembrolizumab regimens in patients ...

Regeneron Pharmaceuticals plans to expand its pipeline into radiopharmaceutical therapies through an up to $4.3 billion collaboration with Telix Pharmaceuticals to co-develop and co-commercialize ...

Five-year overall and lung cancer-specific survival rates were similar for octogenarians and younger patients.

Researchers headed by a team at Keck Medicine of USC have found that corticosteroids, which are commonly prescribed to non-small cell lung cancer (NSCLC) patients to alleviate cancer-related symptoms, ...

HER2-mutated non-small-cell lung cancer (NSCLC) is a rare form of lung cancer where the cancer cells have a mutation that makes them grow and divide in an uncontrolled way. You can best understand ...

The Business Research Company's Non-Small Cell Lung Cancer (NSCLC) Global Market Report 2025 – Market Size, Trends, And Global Forecast 2025-2034 Non-Small Cell Lung Cancer (NSCLC) Global Market ...

Asia-Pacific promises rapid growth, while increasing tobacco use and investments in oncology centers drive demand for ...